These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36192786)

  • 21. β-Hydroxyphosphocarnitine modifies fibrosis, steatosis and improves liver function in non-alcoholic steatohepatitis induced in rats.
    Sánchez-Quevedo J; Ocampo-Rodríguez E; Alvarez-Ayala E; Rodríguez-López A; Duarte-Vázquez MA; Rosado JL; Rodríguez-Fragoso L
    BMC Pharmacol Toxicol; 2022 Sep; 23(1):75. PubMed ID: 36175992
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thyrotropin increases hepatic triglyceride content through upregulation of SREBP-1c activity.
    Yan F; Wang Q; Lu M; Chen W; Song Y; Jing F; Guan Y; Wang L; Lin Y; Bo T; Zhang J; Wang T; Xin W; Yu C; Guan Q; Zhou X; Gao L; Xu C; Zhao J
    J Hepatol; 2014 Dec; 61(6):1358-64. PubMed ID: 25016220
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis.
    Yang RX; Pan Q; Liu XL; Zhou D; Xin FZ; Zhao ZH; Zhang RN; Zeng J; Qiao L; Hu CX; Xu GW; Fan JG
    Lipids Health Dis; 2019 Oct; 18(1):179. PubMed ID: 31639005
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solanum nigrum Polyphenol Extracts Inhibit Hepatic Inflammation, Oxidative Stress, and Lipogenesis in High-Fat-Diet-Treated Mice.
    Chang JJ; Chung DJ; Lee YJ; Wen BH; Jao HY; Wang CJ
    J Agric Food Chem; 2017 Oct; 65(42):9255-9265. PubMed ID: 28982243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Acetyl-CoA Carboxylase Inhibition Improves Multiple Dimensions of NASH Pathogenesis in Model Systems.
    Ross TT; Crowley C; Kelly KL; Rinaldi A; Beebe DA; Lech MP; Martinez RV; Carvajal-Gonzalez S; Boucher M; Hirenallur-Shanthappa D; Morin J; Opsahl AC; Vargas SR; Bence KK; Pfefferkorn JA; Esler WP
    Cell Mol Gastroenterol Hepatol; 2020; 10(4):829-851. PubMed ID: 32526482
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crocin ameliorates hepatic steatosis through activation of AMPK signaling in db/db mice.
    Luo L; Fang K; Dan X; Gu M
    Lipids Health Dis; 2019 Jan; 18(1):11. PubMed ID: 30621686
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diosgenin ameliorates palmitic acid-induced lipid accumulation via AMPK/ACC/CPT-1A and SREBP-1c/FAS signaling pathways in LO2 cells.
    Fang K; Wu F; Chen G; Dong H; Li J; Zhao Y; Xu L; Zou X; Lu F
    BMC Complement Altern Med; 2019 Sep; 19(1):255. PubMed ID: 31519174
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-hepatic steatosis activity of Sicyos angulatus extract in high-fat diet-fed mice and chemical profiling study using UHPLC-qTOF-MS/MS spectrometry.
    An JP; Choi JH; Huh J; Lee HJ; Han S; Noh JR; Kim YH; Lee CH; Oh WK
    Phytomedicine; 2019 Oct; 63():152999. PubMed ID: 31280138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression.
    Abd El-Haleim EA; Bahgat AK; Saleh S
    World J Gastroenterol; 2016 Mar; 22(10):2931-48. PubMed ID: 26973390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genistein has beneficial effects on hepatic steatosis in high fat-high sucrose diet-treated rats.
    Liu H; Zhong H; Yin Y; Jiang Z
    Biomed Pharmacother; 2017 Jul; 91():964-969. PubMed ID: 28514835
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combinations of an acetyl CoA carboxylase inhibitor with hepatic lipid modulating agents do not augment antifibrotic efficacy in preclinical models of NASH and fibrosis.
    Vijayakumar A; Okesli-Armlovich A; Wang T; Olson I; Seung M; Kusam S; Hollenback D; Mahadevan S; Marchand B; Toteva M; Breckenridge DG; Trevaskis JL; Bates J
    Hepatol Commun; 2022 Sep; 6(9):2298-2309. PubMed ID: 35735253
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diosgenin attenuates nonalcoholic hepatic steatosis through the hepatic FXR-SHP-SREBP1C/PPARα/CD36 pathway.
    Chen S; Sun S; Feng Y; Li X; Yin G; Liang P; Yu W; Meng D; Zhang X; Liu H; Zhang F
    Eur J Pharmacol; 2023 Aug; 952():175808. PubMed ID: 37263401
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rutin exhibits hepatoprotective effects in a mouse model of non-alcoholic fatty liver disease by reducing hepatic lipid levels and mitigating lipid-induced oxidative injuries.
    Liu Q; Pan R; Ding L; Zhang F; Hu L; Ding B; Zhu L; Xia Y; Dou X
    Int Immunopharmacol; 2017 Aug; 49():132-141. PubMed ID: 28577437
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High-fat diet from perilla oil induces insulin resistance despite lower serum lipids and increases hepatic fatty acid oxidation in rats.
    Zhang T; Zhao S; Li W; Ma L; Ding M; Li R; Liu Y
    Lipids Health Dis; 2014 Jan; 13():15. PubMed ID: 24422660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of the new thiazolidine derivative LPSF/GQ-02 on hepatic lipid metabolism pathways in non-alcoholic fatty liver disease (NAFLD).
    Araújo S; Soares E Silva A; Gomes F; Ribeiro E; Oliveira W; Oliveira A; Lima I; Lima MDC; Pitta I; Peixoto C
    Eur J Pharmacol; 2016 Oct; 788():306-314. PubMed ID: 27349145
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion.
    Pettinelli P; Del Pozo T; Araya J; Rodrigo R; Araya AV; Smok G; Csendes A; Gutierrez L; Rojas J; Korn O; Maluenda F; Diaz JC; Rencoret G; Braghetto I; Castillo J; Poniachik J; Videla LA
    Biochim Biophys Acta; 2009 Nov; 1792(11):1080-6. PubMed ID: 19733654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. cAMP response element binding protein H mediates fenofibrate-induced suppression of hepatic lipogenesis.
    Min AK; Jeong JY; Go Y; Choi YK; Kim YD; Lee IK; Park KG
    Diabetologia; 2013 Feb; 56(2):412-22. PubMed ID: 23150180
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ellagic acid ameliorates AKT-driven hepatic steatosis in mice by suppressing de novo lipogenesis via the AKT/SREBP-1/FASN pathway.
    Zhang C; Hu J; Sheng L; Yuan M; Wu Y; Chen L; Wang G; Qiu Z
    Food Funct; 2019 Jun; 10(6):3410-3420. PubMed ID: 31123744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha.
    Ren L; Sun D; Zhou X; Yang Y; Huang X; Li Y; Wang C; Li Y
    J Ethnopharmacol; 2019 Mar; 232():176-187. PubMed ID: 30590197
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Suppression of TGF-β/Smad3 signaling pathway by
    Afarin R; Hatami M; Monjezi S; Bineshfar F; Ahangarpour A
    Iran J Basic Med Sci; 2024; 27(9):1096-1104. PubMed ID: 39055878
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.